CN107849092A - Bace1抑制剂肽 - Google Patents

Bace1抑制剂肽 Download PDF

Info

Publication number
CN107849092A
CN107849092A CN201680040557.5A CN201680040557A CN107849092A CN 107849092 A CN107849092 A CN 107849092A CN 201680040557 A CN201680040557 A CN 201680040557A CN 107849092 A CN107849092 A CN 107849092A
Authority
CN
China
Prior art keywords
pro
tyr
glu
val
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680040557.5A
Other languages
English (en)
Chinese (zh)
Inventor
杰里米·比彻姆
佩尔-奥拉·弗雷斯克加德
埃里克·A·基塔斯
维克托·利亚米切夫
吉加尔·帕特尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roynin Vaughn Co
F Hoffmann La Roche AG
Original Assignee
Roynin Vaughn Co
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roynin Vaughn Co, F Hoffmann La Roche AG filed Critical Roynin Vaughn Co
Publication of CN107849092A publication Critical patent/CN107849092A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6478—Aspartic endopeptidases (3.4.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN201680040557.5A 2015-07-24 2016-07-21 Bace1抑制剂肽 Pending CN107849092A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15178162 2015-07-24
EP15178162.2 2015-07-24
PCT/EP2016/067447 WO2017016982A1 (en) 2015-07-24 2016-07-21 Bace1 inhibitor peptides

Publications (1)

Publication Number Publication Date
CN107849092A true CN107849092A (zh) 2018-03-27

Family

ID=53776361

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680040557.5A Pending CN107849092A (zh) 2015-07-24 2016-07-21 Bace1抑制剂肽

Country Status (6)

Country Link
US (1) US10947272B2 (https=)
EP (1) EP3325500A1 (https=)
JP (1) JP6814754B2 (https=)
CN (1) CN107849092A (https=)
HK (1) HK1251593A1 (https=)
WO (1) WO2017016982A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120591368A (zh) * 2025-06-04 2025-09-05 武汉市米来生物科技有限公司 一种具有ace抑制活性的蛋黄多肽的制备方法及应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019094608A1 (en) 2017-11-08 2019-05-16 Denali Therapeutics Inc. Anti-bace1 antibodies and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005097199A1 (en) * 2004-04-08 2005-10-20 Jadolabs Gmbh Tripartite conjugates containing a structure interacting with cell membrane rafts and their use
CN103608344A (zh) * 2011-06-07 2014-02-26 霍夫曼-拉罗奇有限公司 [1，3]噁嗪类
CN104368009A (zh) * 2014-06-25 2015-02-25 中国人民解放军第二军医大学 一种双功能肽修饰的阿尔茨海默病靶向基因递释复合物及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003285892A1 (en) 2002-10-15 2004-05-04 Bristol-Myers Squibb Company Bace binding peptides and uses thereof
US20070149763A1 (en) 2003-10-15 2007-06-28 Bristol-Myers Squibb Company Beta secretase exosite binding peptides and methods for identifying beta secretase modulators
JP2008504329A (ja) 2004-06-29 2008-02-14 ヤド テクノロジーズ ゲゼルシャフト ミット ベシュレンクテル ハフツング 脂質ラフト内の病理プロセスに関係する障害を治療するためのステロイド由来の医薬組成物の使用
JP6134725B2 (ja) * 2011-10-14 2017-05-24 ジェネンテック， インコーポレイテッド Ｂａｃｅ１のペプチド阻害剤
CN110051627A (zh) 2014-09-15 2019-07-26 维罗纳制药公司 包含rpl554的液体吸入制剂
WO2016044951A1 (en) 2014-09-25 2016-03-31 The Hospital For Sick Children Compositions and methods for enhancing hair growth, promoting skin regeneration, and wound healing
CN108064232B (zh) * 2014-11-28 2021-06-15 豪夫迈·罗氏有限公司 肽
US10208087B2 (en) * 2014-11-28 2019-02-19 Hoffmann-La Roche Inc. Peptides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005097199A1 (en) * 2004-04-08 2005-10-20 Jadolabs Gmbh Tripartite conjugates containing a structure interacting with cell membrane rafts and their use
CN103608344A (zh) * 2011-06-07 2014-02-26 霍夫曼-拉罗奇有限公司 [1，3]噁嗪类
CN104368009A (zh) * 2014-06-25 2015-02-25 中国人民解放军第二军医大学 一种双功能肽修饰的阿尔茨海默病靶向基因递释复合物及其制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KORNACKER 等: "An Inhibitor Binding Pocket Distinct from the Catalytic Active Site on Human Beta-APP Cleaving Enzyme", 《BIOCHEMISTRY》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120591368A (zh) * 2025-06-04 2025-09-05 武汉市米来生物科技有限公司 一种具有ace抑制活性的蛋黄多肽的制备方法及应用

Also Published As

Publication number Publication date
JP6814754B2 (ja) 2021-01-20
EP3325500A1 (en) 2018-05-30
WO2017016982A1 (en) 2017-02-02
JP2018523636A (ja) 2018-08-23
US20180179252A1 (en) 2018-06-28
HK1251593A1 (zh) 2019-02-01
US10947272B2 (en) 2021-03-16

Similar Documents

Publication Publication Date Title
Oláh et al. Interactions of pathological hallmark proteins: Tubulin polymerization promoting protein/p25, β-amyloid, and α-synuclein
US10214563B2 (en) Angiotensin type 2 (AT2) receptor agonists and uses thereof
JPH01250370A (ja) 新規アミノ酸イミド誘導体、製法ならびに用途
WO2007145589A1 (en) Peptides that are capable of binding to amyloid-beta peptide.
CN107849092A (zh) Bace1抑制剂肽
JPH0331298A (ja) プロリルエンドペプチターゼ阻害ペプチド
US10208087B2 (en) Peptides
KR20240027091A (ko) 카스파아제-2 억제제 화합물
US10683329B2 (en) Dual-site BACE1 inhibitors
Piacentini et al. Transglutaminase 2 at the crossroads between cell death and survival
JP7553158B2 (ja) アルツハイマー型認知症の予防又は治療用ペプチド組成物
WO2020232056A1 (en) Compositions and methods for the treatment of neurological diseases and disorders
EP4374869A1 (en) Cyclic lipopeptide antibiotic compounds for use in the treatment of protein aggregation disease
CN108676071A (zh) 一种抗Aβ蛋白聚集的七肽及其应用与编码该合成多肽的基因
HK1236041B (zh) 肽
HK1236041A1 (en) Peptides
JP2005325066A (ja) 学習記憶増強剤、学習記憶を増強させる方法
HK1253316B (zh) 肽
WO2017179647A1 (ja) アミロスフェロイド（ａｓｐｄ）結合阻害ペプチド、並びに評価及びスクリーニング方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1251593

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180327

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1251593

Country of ref document: HK